Stocks Like These 3 Have Never Been Cheaper & Could Be About To Head Higher

Bank of America says we’re entering a phase where stocks like these will outperform the market. Here’s why.

A funny thing happened to value stocks in September. After a decade of underperformance, investors started flocking to them on hopes for a U.S.-China trade deal.

But according to Bank of America, value stocks are now cheaper than they’ve been since the financial crisis, creating a buying opportunity.

“Value has never been this cheap vs. Momentum,” wrote Savita Subramanian, the bank’s head of U.S. equity and quantitative strategy, in a note. “Many signals indicate that the recent rotation into Value/out of Momentum could continue.”

The bank says that the only other time in history that value stocks have gotten as cheap as they are now was in 2003 and 2008, when value outperformed momentum stocks by 22% and 69%, respectively, over the following 12 months.

The USA Value Factor iShares Edge MSCI ETF—with top holdings including AT&T (NYSE: T), Citigroup (NYSE: C), and Pfizer (NYSE: PFE)—is up just under 21% so far this year. While the ETF is slightly lagging the S&P 500’s 23% gain, it is outpacing the corresponding momentum ETF, the USA Momentum Factor iShares Edge MSCI ETF, by almost 1%.

In the last week, all three major indexes have surged to new all-time highs as optimism has risen as the U.S. and China inch closer to signing the phase one limited trade deal. Add to that, recent economic data has looked solid with U.S. services activities topping estimates for October, and job creation last month easily beating expectations.

And according to Subramanian, that’s a positive sign for value stocks.

“Some recent signs of stabilization in macro data also supports that the downturn might be bottoming and the Value rotation could continue,” he said.

“The ‘Downturn’ phase in our US Regime Indicator has historically lasted eight months on average (we’re now in month eight),” Subramanian wrote in the note. “The next phase is ‘Early Cycle,’ when Value typically outperforms.”

But Subramanian isn’t the only voice touting value stocks now.

AQR Capital’s Cliff Asness also gave them a stamp of approval this week when he said that it may be time to buy into value stocks after the group has been under pressure for the last decade. 

“We think the first eight-plus years of value’s recent 10-year losing streak were ‘rational’ (for want of a better word)… In contract, the last almost two years have seen value lose for ‘irrational’ reasons,” Asness wrote in a blog post. “Value fundamentals have not come in worse over this recent painful period, it’s prices alone that have gone the wrong way.”

“If you believe, as we do, that value is a good long-term strategy, and an important part (not all) of an investment process, we would recommend a modest extra amount of value than the norm,” Asness continued. “To the skeptics we would ask ‘if not now, when?’ If the answer is ‘only when it’s as bad as the tech bubble’ we just think you’re making the wrong call.”

 
Trending Ideas

Featured Stocks On The Move

Daily Rundown

Top 3 Stocks in Leading Sectors
  • 3 Software Stocks To Buy Now

    International Business Machines Corporation (IBM) International Business Machines Corporation (IBM) is a global leader in cloud computing, AI, and enterprise software. The company provides IT infrastructure, cybersecurity, and quantum computing... Read More

  • 3 Food Stocks To Buy Now

    The Campbell’s Company (CPB) The Campbell’s Company is a leading producer of packaged foods and beverages, known for its soups, sauces, and snacks. With brands like Campbell’s, Pepperidge Farm, and... Read More

  • 3 Utility Stocks To Buy Now

    IDACORP, Inc. (IDA) IDACORP, Inc. is a utility holding company that provides electricity through its subsidiary, Idaho Power. The company focuses on renewable energy initiatives, grid modernization, and sustainable power... Read More

  • 3 Biotechnology Stocks To Buy Now

    Xeris Biopharma Holdings, Inc. (XERS) Xeris Biopharma Holdings, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative injectable drug formulations. Its proprietary technology enhances drug stability and... Read More

  • 3 Consumer Service Stocks To Buy Now

    TripAdvisor, Inc. (TRIP) TripAdvisor, Inc. operates the world’s largest travel guidance platform, offering user-generated reviews, price comparisons, and booking services for hotels, attractions, and restaurants worldwide. Chart Wynn Resorts, Limited... Read More

  • 3 Software Stocks To Buy Now

    Udemy, Inc. (UDMY) Udemy, Inc. is an online learning platform offering a vast catalog of courses across various fields. The company connects learners with expert instructors, providing affordable and accessible... Read More

  • 3 Energy Stocks To Buy Now

    Ranger Energy Services, Inc. (RNGR) Ranger Energy Services, Inc. provides well services and support for oil and gas production. The company specializes in high-spec rig solutions, completion services, and workover... Read More

  • 3 Pharmaceutical Stocks To Buy Now

    ACADIA Pharmaceuticals Inc. (ACAD) ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on developing therapies for central nervous system disorders. The company’s lead product, NUPLAZID, is used to treat Parkinson’s... Read More